FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+50.76%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$917M
AUM Growth
+$917M
(-3.1%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-26.18%
Top 10 Holdings %
Top 10 Hldgs %
89.15%
Holding
18
New
2
Increased
5
Reduced
1
Closed
3
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$27M |
| 2 |
Dianthus Therapeutics
DNTH
|
$25M |
| 3 |
Geron
GERN
|
$22M |
| 4 |
Enliven Therapeutics
ELVN
|
$18.8M |
| 5 |
Viridian Therapeutics
VRDN
|
$8.34M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$176M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$77.5M |
| 3 |
Apogee Therapeutics
APGE
|
$59.3M |
| 4 |
argenx
ARGX
|
$43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $188M | 20.53% | 2,360,077 | – | – |
|
2
Nuvalent
NUVL
$5.52B
| $145M | 15.75% | 1,924,626 | – | – |
|
|
3
Apogee Therapeutics
APGE
$2.17B
| $136M | 14.84% | 2,048,647 -892,529 | -30% | -$59.3M |
|
|
4
Dianthus Therapeutics
DNTH
$759M
| $82.9M | 9.03% | 2,762,837 +834,334 | +43% | +$25M |
|
5
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $63.2M | 6.89% | 3,204,841 +321,620 | +11% | +$6.35M |
|
|
6
Enliven Therapeutics
ELVN
$1.2B
| $56.3M | 6.14% | 3,202,798 +1,071,429 | +50% | +$18.8M |
|
7
Astria Therapeutics
ATXS
$349M
| $50M | 5.45% | 3,554,129 | – | – |
|
|
8
Viridian Therapeutics
VRDN
$1.5B
| $32.3M | 3.52% | 1,845,813 +476,190 | +35% | +$8.34M |
|
9
Merus
MRUS
$4.98B
| $32.3M | 3.52% | 717,254 | – | – |
|
10
Cogent Biosciences
COGT
$1.69B
| $31.8M | 3.46% | 4,725,641 +1,166,666 | +33% | +$7.84M |
|
|
11
Protagonist Therapeutics
PTGX
$3.67B
| $27M | 2.94% | +931,890 | New | +$27M |
|
12
Tyra Biosciences
TYRA
$675M
| $22.9M | 2.49% | 1,393,329 | – | – |
|
|
13
Geron
GERN
$893M
| $22M | 2.4% | +6,666,667 | New | +$22M |
|
14
Spyre Therapeutics
SYRE
$996M
| $14.4M | 1.56% | 378,421 | – | – |
|
15
Terns Pharmaceuticals
TERN
$609M
| $13.4M | 1.46% | 2,040,000 | – | – |
|
|
16
argenx
ARGX
$43.6B
| – | – | -112,903 | Closed | -$43M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – | -1,245,929 | Closed | -$77.5M |
|
|
IMGN
18
DELISTED
Immunogen Inc
IMGN
| – | – | -5,929,592 | Closed | -$176M |
|